Stifel Nicolaus Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Key Points

• Stifel Nicolaus raised Enliven Therapeutics’ price target to $82 from $80 and maintained a “buy” rating, implying approximately 35.8% upside from the current price.
• Analyst sentiment is generally positive, with six Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average target price of $72.67.
• Shares rose 1.1% to $60.37, near their 52-week high, despite the company reporting a quarterly loss of $0.49 per share—$0.10 worse than analysts expected. Insiders have sold 32,036 shares worth about $1.43 million over the past 90 days.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its price target lifted by research analysts at Stifel Nicolaus from $80.00 to $82.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. Stifel Nicolaus' price target would suggest a potential upside of 35.83% from the stock's current price.

A number of other analysts also recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Mizuho upped their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an "outperform" rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, May 11th. The Goldman Sachs Group raised their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday. Finally, HC Wainwright boosted their price target on Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research note on Thursday, July 9th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $72.67.

Enliven Therapeutics Stock Up 1.1%

NASDAQ ELVN traded up $0.67 during mid-day trading on Thursday, hitting $60.37. The stock had a trading volume of 145,349 shares, compared to its average volume of 1,279,107. The company has a 50 day simple moving average of $47.81 and a 200 day simple moving average of $39.29. The company has a market cap of $3.68 billion, a price-to-earnings ratio of -36.17 and a beta of 0.27. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts anticipate that Enliven Therapeutics will post -1.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction that occurred on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares in the company, valued at $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director owned 41,884 shares of the company's stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 32,036 shares of company stock valued at $1,430,676. Company insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after buying an additional 594 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Enliven Therapeutics by 4.3% in the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock worth $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV acquired a new position in Enliven Therapeutics during the 1st quarter worth approximately $38,000. Finally, Swiss National Bank raised its position in shares of Enliven Therapeutics by 1.7% during the 4th quarter. Swiss National Bank now owns 64,273 shares of the company's stock worth $990,000 after acquiring an additional 1,100 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source